Protagonist Therapeutics, Inc.

Protagonist Therapeutics Misses on EPS — Stock Down 0.58%

Protagonist Therapeutics reported a significant miss on EPS, which contributed to a slight decline in stock price by 0.58%. The lack of revenue data and absence of guidance may raise concerns among investors about the company's future performance. The focus on clinical trials suggests that management is prioritizing long-term growth over short-term financial metrics.